Cantor Fitzgerald downgraded shares of NexImmune (NASDAQ:NEXI – Get Rating) from an overweight rating to a neutral rating in a report released on Wednesday, The Fly reports. Cantor Fitzgerald also issued estimates for NexImmune’s FY2022 earnings at ($2.52) EPS and FY2023 earnings at ($0.93) EPS.
A number of other equities analysts also recently commented on the stock. Raymond James downgraded shares of NexImmune from an outperform rating to a market perform rating in a report on Tuesday, November 15th. Barclays reduced their price objective on shares of NexImmune from $7.00 to $2.00 and set an overweight rating for the company in a report on Tuesday, August 16th.
NexImmune Price Performance
Shares of NEXI opened at $0.45 on Wednesday. The company’s fifty day moving average is $0.64 and its 200-day moving average is $1.33. NexImmune has a 12 month low of $0.43 and a 12 month high of $10.38. The firm has a market cap of $10.87 million, a price-to-earnings ratio of -0.17 and a beta of 1.95.
Insider Activity at NexImmune
Institutional Investors Weigh In On NexImmune
Several institutional investors have recently modified their holdings of the business. Smith Salley & Associates bought a new position in NexImmune during the 1st quarter worth approximately $46,000. Bailard Inc. bought a new position in NexImmune in the second quarter valued at approximately $33,000. Raymond James & Associates bought a new position in NexImmune in the first quarter valued at approximately $87,000. Sei Investments Co. bought a new position in NexImmune in the second quarter valued at approximately $43,000. Finally, Goldman Sachs Group Inc. bought a new position in NexImmune in the second quarter valued at approximately $47,000. Institutional investors and hedge funds own 34.45% of the company’s stock.
NexImmune Company Profile
NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
- Get a free copy of the StockNews.com research report on NexImmune (NEXI)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.